LEXARIA BIOSCIENCE CORP (LEXX)
US52886N4060 - Common Stock
We assign a fundamental rating of 3 out of 10 to LEXX. LEXX was compared to 198 industry peers in the Pharmaceuticals industry. While LEXX has a great health rating, there are worries on its profitability. While showing a medium growth rate, LEXX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
LEXX had negative earnings in the past year.
In the past year LEXX has reported a negative cash flow from operations.
LEXX had negative earnings in each of the past 5 years.
In the past 5 years LEXX always reported negative operating cash flow.
1.2 Ratios
LEXX has a worse Return On Assets (-85.62%) than 75.38% of its industry peers.
Looking at the Return On Equity, with a value of -83.41%, LEXX is in line with its industry, outperforming 43.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.62% | ||
| ROE | -83.41% | ||
| ROIC | N/A |
ROA(3y)-113.15%
ROA(5y)-126.26%
ROE(3y)-113.63%
ROE(5y)-133.7%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LEXX's Gross Margin of 96.16% is amongst the best of the industry. LEXX outperforms 97.95% of its industry peers.
LEXX's Gross Margin has declined in the last couple of years.
LEXX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.16% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.19%
GM growth 5Y-2.83%
2. Health
2.1 Basic Checks
LEXX does not have a ROIC to compare to the WACC, probably because it is not profitable.
LEXX has more shares outstanding than it did 1 year ago.
LEXX has more shares outstanding than it did 5 years ago.
LEXX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -172.20, we must say that LEXX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -172.20, LEXX is doing worse than 96.41% of the companies in the same industry.
There is no outstanding debt for LEXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -172.2 |
ROIC/WACCN/A
WACC8.08%
2.3 Liquidity
LEXX has a Current Ratio of 66.29. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.
LEXX has a Current ratio of 66.29. This is amongst the best in the industry. LEXX outperforms 100.00% of its industry peers.
LEXX has a Quick Ratio of 66.29. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.
LEXX has a better Quick ratio (66.29) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 66.29 | ||
| Quick Ratio | 66.29 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 39.26% over the past year.
LEXX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.37%.
The Revenue for LEXX have been decreasing by -11.76% on average. This is quite bad
EPS 1Y (TTM)39.26%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q72.57%
Revenue 1Y (TTM)10.37%
Revenue growth 3Y-9.47%
Revenue growth 5Y-11.76%
Revenue growth Q2Q262.5%
3.2 Future
The Earnings Per Share is expected to grow by 13.30% on average over the next years. This is quite good.
Based on estimates for the next years, LEXX will show a very strong growth in Revenue. The Revenue will grow by 118.90% on average per year.
EPS Next Y51.36%
EPS Next 2Y24.5%
EPS Next 3Y13.3%
EPS Next 5YN/A
Revenue Next Year51.65%
Revenue Next 2Y75.24%
Revenue Next 3Y-25.99%
Revenue Next 5Y118.9%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LEXX. In the last year negative earnings were reported.
Also next year LEXX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LEXX's earnings are expected to grow with 13.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.5%
EPS Next 3Y13.3%
5. Dividend
5.1 Amount
No dividends for LEXX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LEXARIA BIOSCIENCE CORP
NASDAQ:LEXX (5/1/2024, 7:07:15 PM)
After market: 3.38 -0.11 (-3.15%)3.49
+0.4 (+12.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap44.99M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.62% | ||
| ROE | -83.41% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.16% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 66.29 | ||
| Quick Ratio | 66.29 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)39.26%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y51.36%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)10.37%
Revenue growth 3Y-9.47%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y